Mm-121 (Not yet branded)
Other Medications
Description
MM-121 is a fully human monoclonal antibody that targets the ErbB3 receptor, developed for treatment of advanced solid tumors including colorectal cancer. This targeted therapy is designed to block ErbB3-mediated signaling pathways that contribute to tumor growth and resistance to other cancer treatments. MM-121 has been evaluated in combination with established therapies such as cetuximab and irinotecan in patients with advanced cancers.
Mechanism of Action
MM-121 binds specifically to the ErbB3 receptor (HER3), blocking its activation and subsequent downstream signaling through the PI3K/AKT pathway. By inhibiting ErbB3 signaling, MM-121 aims to overcome resistance mechanisms that tumors develop against EGFR-targeted therapies and enhance the effectiveness of combination treatment regimens.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.